Watch These Hot Ones: BlackBerry Ltd (NASDAQ:BBRY), Apricus Biosciences (NASDAQ:APRI), Hovnanian Enterprises Inc. (NYSE:HOV), Vale S.A. (NYSE:VALE), Hemispherx Biopharma (NYSEMKT:HEB)


BlackBerry Ltd (NASDAQ:BBRY) shares increased 0.23% in last trading session and ended the day at $8.83. BBRY Gross Margin is 48.80% and its has a return on assets of -4.60%. BlackBerry Ltd (NASDAQ:BBRY) quarterly performance is -4.85%. BlackBerry Ltd (NASDAQ:BBRY)’s CEO John Chen, looking to help BlackBerry sell phones and services to hospitals, says that the company might build bacteria-free handsets. The executive made it clear that such a phone is not yet being developed by the company. The chief medical information officer at regional healthcare provider Mackenzie Health, Aviv Gladman, says that preventing patients from transferring bacteria and infections back and forth is a “huge issue.”

Apricus Biosciences, Inc. (NASDAQ:APRI) ended the last trading day at $1.70. Company weekly volatility is calculated as 5.42% and price to cash ratio as 5.29. Apricus Biosciences, Inc. (NASDAQ:APRI) showed a weekly performance of 3.66%. Apricus Biosciences, Inc. (NASDAQ:APRI) on 15 June, announced that it has enrolled the last patient in its RayVa(TM)Phase 2a proof-of-concept study. The Company expects to report top-line data in the third quarter of 2015 in advance of potentially moving RayVa into a pivotal Phase 2b trial following further guidance discussions with the FDA.

On 24 June, Hovnanian Enterprises Inc. (NYSE:HOV) shares advanced 2.21% and was closed at $2.78. HOV EPS growth in last 5 year was 17.10%. Hovnanian Enterprises Inc. (NYSE:HOV) year to date (YTD) performance is -32.69%. Zacks downgraded shares of Hovnanian Enterprises (NYSE:HOV) from a hold rating to a sell rating in a research note.

Vale S.A. (NYSE:VALE) shares moved down -0.62% in last trading session and ended the day at $6.40. VALE Gross Margin is 32.30% and its has a return on assets of -2.60%. Vale S.A. (NYSE:VALE) quarterly performance is 6.26%. Vale S.A. (NYSE:VALE) is considering selling about 25 percent to 30 percent of its base metals business in an initial public offering. Work on the transaction continues, although the Rio de Janeiro-based miner will only proceed if nickel and copper prices reach “appropriate” levels, Investor Relations Director Rogerio Nogueira said in Sao Paulo Wednesday.

Hemispherx Biopharma, Inc. (NYSEMKT:HEB) caters to the Healthcare space. Its weekly performance is -5.04%. On the last day of trading company shares ended up $0.22. Hemispherx Biopharma, Inc. (NYSEMKT:HEB) distance from 50-day simple moving average (SMA50) is -8.77%. Hemispherx Biopharma, Inc. (NYSEMKT:HEB) on June 4, 2015, announced that the United States District Court for the Eastern District of Pennsylvania has granted preliminary approval of a settlement of the currently pending securities class action, Frater v. Hemispherx Biopharma, Inc. A final settlement hearing has been scheduled for July 22, 2015.


Leave a Reply

Your email address will not be published. Required fields are marked *